Skip to main content
Livermore
Livermore
ZHEN

Inozyme Pharma, Inc.

INZYDelisted Jul 1, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001693011

Inozyme Pharma, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 3, 2025; 87 institutions reported holding it in 13F filings for Q2 2025, worth $202.3M in total; no superinvestor held it.

13F holders, Q3 2021

Institutional positions in Inozyme Pharma, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
52
+2 vs. Q2 2021
Shares held
17.5M
−2.30M (−11.6%) vs. Q2 2021
Total value
$202.7M
−$134.4M (−39.9%) vs. Q2 2021
New holders
6
18 more added
Sold out
4
14 more reduced

Compare with Q2 2021: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting INZY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2021: 52 institutions
Q1 2021: 55 institutionsQ2 2021: 50 institutionsQ3 2021: 52 institutionsQ4 2021: 51 institutionsQ1 2022: 50 institutionsQ2 2022: 47 institutionsQ3 2022: 39 institutionsQ4 2022: 37 institutionsQ1 2023: 50 institutionsQ2 2023: 74 institutionsQ3 2023: 77 institutionsQ4 2023: 80 institutionsQ1 2024: 89 institutionsQ2 2024: 90 institutionsQ3 2024: 89 institutionsQ4 2024: 105 institutionsQ1 2025: 97 institutionsQ2 2025: 87 institutionsQ3 2025: 0 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ3 2021: $202.7M
Q1 2021: $379.4MQ2 2021: $337.1MQ3 2021: $202.7MQ4 2021: $118.2MQ1 2022: $71.2MQ2 2022: $149.4MQ3 2022: $82.7MQ4 2022: $30.4MQ1 2023: $183.4MQ2 2023: $190.3MQ3 2023: $204.6MQ4 2023: $213.3MQ1 2024: $382.0MQ2 2024: $240.1MQ3 2024: $285.5MQ4 2024: $145.1MQ1 2025: $42.5MQ2 2025: $202.3MQ3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding INZY and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20250$0
Q2 202587$202.3M
Q1 202597$42.5M
Q4 2024105$145.1M
Q3 202489$285.5M
Q2 202490$240.1M
Q1 202489$382.0M
Q4 202380$213.3M
Q3 202377$204.6M
Q2 202374$190.3M
Q1 202350$183.4M
Q4 202237$30.4M
Q3 202239$82.7M
Q2 202247$149.4M
Q1 202250$71.2M
Q4 202151$118.2M
Q3 202152$202.7M
Q2 202150$337.1M
Q1 202155$379.4M

Institutions, Q3 2021

Shares, value and share of portfolio for each institution holding Inozyme Pharma, Inc.; share changes are against Q2 2021.

Institutions holding INZY in Q3 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Wells Fargo & Company48$1.00K0.00%00.0%Unchanged
Daiwa Securities Group Inc.44$1.00K0.00%00.0%Unchanged
Nisa Investment Advisors, LLC200$2.00K0.00%00.0%Unchanged
Bank of America Corp287$4.00K0.00%−2,217−88.5%Reduced
Penserra Capital Management LLC540$6.00K0.00%+5+0.9%Added
Ameritas Investment Partners, Inc.692$8.00K0.00%00.0%Unchanged
Tower Research Capital LLC (TRC)805$9.00K0.00%−374−31.7%Reduced
Legal & General Group Plc1,147$13.0K0.00%00.0%Unchanged
Royal Bank of Canada1,841$21.0K0.00%+857+87.1%Added
Citigroup Inc3,104$36.0K0.00%+996+47.2%Added
Acadian Asset Management LLC3,676$42.0K0.00%+3,676New
DekaBank Deutsche Girozentrale7,000$78.0K0.00%00.0%Unchanged
California State Teachers Retirement System7,730$90.0K0.00%−12,137−61.1%Reduced
American International Group, Inc.7,875$91.0K0.00%−187−2.3%Reduced
Ensign Peak Advisors, Inc7,991$93.0K0.00%00.0%Unchanged
Deutsche Bank AG8,276$96.0K0.00%−266−3.1%Reduced
New York State Common Retirement Fund10,453$121.0K0.00%+1,651+18.8%Added
Millennium Management LLC11,064$128.0K0.00%−50,249−82.0%Reduced
SG Americas Securities, LLC11,611$135.0K0.00%+11,611New
Rhumbline Advisers13,462$156.0K0.00%+675+5.3%Added
Goldman Sachs Group Inc16,565$192.0K0.00%−2,745−14.2%Reduced
Overbrook Management Corp16,726$194.0K0.04%00.0%Unchanged
Morgan Stanley17,994$209.0K0.00%−24,760−57.9%Reduced
Jacobs Levy Equity Management, Inc21,037$244.0K0.00%+21,037New
Marshall Wace, LLP33,408$387.0K0.00%−6,794−16.9%Reduced
Charles Schwab Investment Management Inc36,427$423.0K0.00%−25,490−41.2%Reduced
Bank of New York Mellon Corp40,418$469.0K0.00%+3,872+10.6%Added
Nuveen Asset Management, LLC47,662$565.0K0.00%+268+0.6%Added
Commonwealth Equity Services, LLC65,781$762.0K0.00%00.0%Unchanged
Laurion Capital Management LP70,700$819.0K0.01%+70,700New
Citadel Advisors LLC94,466$1.09M0.00%−76,600−44.8%Reduced
Baker Bros. Advisors LP106,999$1.24M0.01%00.0%Unchanged
Russell Investments Group, Ltd.115,516$1.34M0.00%+113,015+4,518.8%Added
Northern Trust Corp116,101$1.34M0.00%−4,642−3.8%Reduced
Caas Capital Management LP135,398$1.57M0.12%+135,398New
State Street Corp188,267$2.18M0.00%+18,378+10.8%Added
Geode Capital Management, LLC198,624$2.30M0.00%+18,952+10.5%Added
OrbiMed Advisors LLC294,000$3.41M0.04%+105,296+55.8%Added
MPM Oncology Impact Management LP320,724$3.72M0.58%+320,724New
JPMorgan Chase & Co331,891$3.85M0.00%+315,232+1,892.3%Added
Wellington Management Group LLP364,600$4.23M0.00%−364,954−50.0%Reduced
FMR LLC609,380$7.06M0.00%00.0%Unchanged
Vanguard Group Inc611,185$7.08M0.00%+275,899+82.3%Added
Rock Springs Capital Management LP850,015$9.85M0.21%+9,743+1.2%Added
BlackRock Inc.900,719$10.4M0.00%+846+0.1%Added
CHI Advisors LLC920,264$10.7M3.11%−7,000−0.8%Reduced
Suvretta Capital Management, LLC986,400$11.4M0.19%+621,228+170.1%Added
Adage Capital Partners GP, L.L.C.1,467,828$17.0M0.03%+179,156+13.9%Added
Pivotal bioVenture Partners Investment Advisor LLC1,591,154$18.4M6.52%00.0%Unchanged
Sofinnova Investments, Inc.2,028,308$23.5M1.51%00.0%Unchanged
Deerfield Management Company, L.P. (Series C)2,344,786$27.2M0.53%+165,801+7.6%Added
NEA Management Company, LLC2,444,379$28.3M0.36%00.0%Unchanged
Ra Capital Management, L.P.0$00.00%−2,003,653−100.0%Sold out
Novo Holdings A/S0$00.00%−1,867,706−100.0%Sold out
Burrage Capital Management LLC0$00.00%−242,517−100.0%Sold out
UBS Group AG0$00.00%−48−100.0%Sold out